PerkinElmer and Procognia to Offer Breakthrough Protein Array Platform
PerkinElmer, Inc. (NYSE: PKI), a global leader in health sciences, and Procognia, a leading developer of innovative and transformational technologies in the field of proteomics, today announced an exclusive distribution and co-marketing agreement to deliver the only complete solution for high-throughput and high-resolution analysis of the glycosylation of proteins. Procognia’s U-c fingerprint lectin array-based platform is being combined with PerkinElmer’s advanced instrumentation, the Protein Array Workstation(TM) and the recently introduced ProScanArray(TM) HT, to offer the industry’s first high-throughput, high-resolution glycoanalysis capability. Certain scientific estimates indicate that more than 60% of critical biological functions involve glycosylated proteins. This new technology will drive significant advancements in the understanding of protein function and structure.
U-c fingerprint technology requires no sample purification or pretreatment, and allows the quantitative analysis of 20 samples in approximately three hours. In addition, glycosylation analysis throughout the therapeutic protein discovery, development and manufacturing process will bring biopharmaceutical companies closer to satisfying the FDA’s PAT (Process Analytical Technology) initiative. This technology is focused on reducing the time and cost of producing higher quality biopharmaceuticals.
“Procognia is a leader in proteomic technologies and together with PerkinElmer’s extensive capabilities, we can now offer the industry’s first complete high-throughput, high-resolution glycoanalysis platform for academic, biotech, and pharmaceutical customers,” said Peter Coggins, PhD., president, PerkinElmer Life and Analytical Sciences.
“We believe we can accelerate adoption of Procognia’s U-c fingerprint technology and firmly establish it as the gold standard in the monitoring and control of glycosylation of proteins by teaming with a global life sciences solutions provider like PerkinElmer,” said Ron Long, CEO of Procognia Ltd.
About PerkinElmer
PerkinElmer, Inc. is a global technology leader focused in the following businesses – Life and Analytical Sciences, Optoelectronics and Fluid Sciences. Combining operational excellence and technology expertise with an intimate understanding of our customers’ needs, PerkinElmer provides products and services in health sciences and other advanced technology markets that require innovation, precision and reliability. The Company serves customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.
About Procognia
Procognia, a 2004 World Economic Forum Technology Pioneer award winner, is focused on developing and commercializing its cutting edge proprietary technologies that will enable the unraveling of disease mechanisms and the discovery and development of drugs to treat those diseases. In addition to developing the glycoanalysis platform, Procognia has developed arrays of biologically related proteins that retain their physiological function in the array format. Procognia was formed in April 2002 with a corporate headquarters and manufacturing in Maidenhead, United Kingdom. Commercial operations are run from the United Kingdom and Exton, PA, United States, and supported by R&D facilities in Maidenhead, United Kingdom and Ashdod, Israel. Additional information available at www.procognia.com .
